Mersana Therapeutics
MRSN | NASDAQ
$29.08
$0.00 (0.00%)
At close: Jan 5, 2026, 3:55 PM ET
Mersana Therapeutics Company Profile
Company profile explainedCompany Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Martin H. Huber | President, Chief Executive Officer & Director |
| Alejandra Veronica Carvajal | Senior Vice President, Secretary & Chief Legal Officer |
| Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer |
| Ashish Mandelia | Vice President & Chief Accounting Officer |
| Chuck Miller | Senior Vice President of Regulatory Affairs |
| Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications |
| Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. |
| Mikhail Papisov | Co-Founder |
| Mohan Bala | Senior Vice President & Chief Development Officer |
| Timothy Lowinger | Senior Vice President and Chief Science & Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 17, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 17, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jan 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jan 16, 2026 | 15-12G | Filing |
| Jan 09, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jan 08, 2026 | EFFECT | Filing |
| Jan 08, 2026 | SC 13D/A | [Amend] Filing |
| Jan 06, 2026 | 4 | Filing |
| Jan 06, 2026 | 4 | Filing |
Mersana Therapeutics
| Country | United States |
| IPO Date | Jun 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Martin H. Huber |
Contact Details
840 Memorial Drive Cambridge,
Massachusetts 02139 United States
Stock Details
| Ticker Symbol | MRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001442836 |
| CUSIP Number | 59045L205 |
| ISIN Number | US59045L2051 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MRSN